a Division of OPKO Health, Inc.
© 2014 OPKO All rights reserved
The Challenge of Prostate Biopsy Decision Making
The Need for Improved Diagnostic Information
The OPKO 4Kscore Test - Adding Clarity to Shared Decision Making
Elements of the 4Kscore Test
The 4Kscore test was developed by OPKO Lab and is performed by OPKO Lab at its CLIA-accredited laboratory facility. The 4Kscore Test relies on the measurement of four prostate-specific kallikreins in blood: Total PSA, Free PSA, Intact PSA, and Human Kallikrein 2 (hK2). The blood test results are combined in an algorithm with patient age, DRE (nodules, no nodules), prior negative biopsy (yes/no). The result is a patient specific probability for finding a high-grade, Gleason score 7 or higher prostate cancer upon biopsy.
4Kscore Test: Rigorous Clinical Development
Data from the US Clinical Study
The biomarkers and algorithms utilized in the 4Kscore Test are based on over a decade of research conducted by scientists at Memorial Sloan Kettering Cancer Center and leading research centers in Europe on over 10,000 patients.
• The PSA test is not specific for prostate cancer. An elevated PSA can also be caused by benign prostate disease
To learn more about the 4Kscore Test,
To learn more, call: 1 (877) 922-8364
Personal risk for high-grade prostate cancer ... from a blood test